3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Conditions
Neoplasms
9
Breast Neoplasms
6
Lymphoma, B-Cell, Marginal Zone
4
Barrett Esophagus
4
Lymphoma, Large B-Cell, Diffuse
3
Inflammation
3
Head and Neck Neoplasms
3
Zollinger-Ellison Syndrome
2
Stomach Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
2
Pancreatic Neoplasms
2
Lymphoma
2
Colorectal Neoplasms
2
Uterine Cervical Dysplasia
1
Triple Negative Breast Neoplasms
1
Stomach Ulcer
1
Solid Tumours
1
Solid Tumor
1
Prostatic Neoplasms, Castration-Resistant
1
Prostatic Neoplasms
1
Prostate Cancer Patients
1
Precancerous Gastric Lesions
1
Pharmacokinetics of MDV3100
1
Peripheral Nervous System Diseases
1
Ovarian Neoplasms
1
Obesity
1
Mouth Neoplasms
1
Melanoma
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Mantle-Cell
1
Interventions
vandetanib
12
cabozantinib
8
selpercatinib
5
Sorafenib
5
Everolimus
5
Magnetic Resonance Spectroscopy
3
Capecitabine
3
sargramostim
2
pralsetinib
2
lutetium Lu 177 dotatate
2
lenvatinib
2
Trastuzumab
2
Temozolomide
2
Sunitinib
2
Specimen Handling
2
Octreotide
2
High-Energy Shock Waves
2
Gefitinib
2
Doxorubicin
2
yeast-CEA vaccine
1
veliparib
1
vatalanib
1
tumor necrosis factor-alpha, CNGRC fusion protein, human
1
tipifarnib
1
temsirolimus
1
tanespimycin
1
sacubitril and valsartan sodium hydrate drug combination
1
rovalpituzumab tesirine
1
ponatinib
1
pentetreotide
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Carcinoma, Medullary
×
Omeprazole
×
Clear all
NCT01539655
2017-05-02
Vandetanib
Sanofi
Phase 1
Completed
34 enrolled